Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 6:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,054 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Sensitive Skin Clear all

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 9
States / cities: Anaheim, California • Encino, California • Miami, Florida + 6 more

Conditions: Healthy, Dermatitis, Atopic
Interventions: LY3844583, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions: LPX-TI641, Placebo; Drug
Lead sponsor: LAPIX Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Fargo, North Dakota • Dallas, Texas

Conditions: Atopic Dermatitis, Psoriasis, Contact Dermatitis
Interventions: Not listed
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Eczema, Atopic Dermatitis
Interventions: Experimental: B244; Drug
Lead sponsor: AOBiome LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Bryant, Arkansas • Los Angeles, California • Plainfield, Indiana + 3 more

Conditions: Atopic Dermatitis
Interventions: Lebrikizumab, Placebo, TCS Cream; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 13 more

Conditions: Atopic Dermatitis
Interventions: Dupilumab, Midazolam, Omeprazole, Warfarin, Caffeine, Metoprolol; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Little Rock, Arkansas • Centennial, Colorado • Minneapolis, Minnesota + 2 more

Conditions: Chronic Spontaneous Urticaria
Interventions: Lirentelimab (AK002), Placebo; Drug · Other
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 51
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 44 more

Conditions: Hereditary Angioedema (HAE)
Interventions: navenibart, Placebo; Drug
Lead sponsor: Astria Therapeutics, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more

Conditions: Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis
Interventions: 5 mg Serlopitant Tablets; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 558 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 46
States / cities: Birmingham, Alabama • Fremont, California • North Hollywood, California + 42 more

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Acne Vulgaris
Interventions: Acne Mask; Device
Lead sponsor: Johnson & Johnson Consumer Inc. (J&JCI); Industry
Eligibility: 12 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf); Biological
Lead sponsor: Shire; Industry
Eligibility: 1 Year and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 30
States / cities: Scottsdale, Arizona • Bentonville, Arkansas • Los Angeles, California + 27 more

Conditions: Atopic Dermatitis
Interventions: Galvokimig, Placebo; Biological · Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more

Conditions: Atopic Dermatitis
Interventions: SB414 2%, SB414 6%, Vehicle; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Coral Gables, Florida • Sweetwater, Florida • Boise, Idaho + 6 more

Conditions: Atopic Dermatitis
Interventions: Bodewell Calming Cream; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Michael O'Connor; Other
Eligibility: 18 Years to 90 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Atopic Dermatitis
Interventions: Text message to cell phone; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 10 Years to 17 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Moderate to Severe Atopic Dermatitis
Interventions: ISB 830 - Part 1 Group 1, ISB 830 - Part 1 Group 2, ISB 830 - Part 1 Group 3, Placebo - Part 1 Group 4, ISB 830 - Part 2 Group 5, Placebo - Part 2 Group 6; Drug
Lead sponsor: Ichnos Sciences SA; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 34
States / cities: Birmingham, Alabama • Clovis, California • Rolling Hills Estates, California + 29 more

Conditions: Hereditary Angioedema
Interventions: CSL312, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more

Conditions: Dermatitis, Atopic
Interventions: VTP-38543, Vehicle with Transcutol®P, Vehicle without Transcutol®P; Drug · Other
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: West Dundee, Illinois • Fort Gratiot, Michigan • New York, New York + 2 more

Conditions: Hereditary Angioedema (HAE), Angioedema
Interventions: Lanadelumab 150 mg, Lanadelumab 300 mg; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years and older
U.S. locations: 14
States / cities: Scottsdale, Arizona • Santa Monica, California • Walnut Creek, California + 10 more

Conditions: Atopic Dermatitis
Interventions: Moisturizer Containing Isosorbide Diesters and Colloidal Oatmeal, Moisturizer containing Colloidal Oatmeal only; Other
Lead sponsor: Integrative Skin Science and Research; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Atopic Dermatitis
Interventions: Ruxolitinib cream, Vehicle; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Culver City, California

Search by objective public record fields.

A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis

A Study of LY3844583 in Healthy Participants and Participants With Atopic Dermatitis

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Molecular and Cellular Characterization of Spongiotic Dermatitis

A Study of B244 Delivered as a Topical Spray to Assess Safety in Pediatric Subjects With Atopic Dermatitis

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)

A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria

A Study of Navenibart in Participants With Hereditary Angioedema

Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris

Open-Label C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Bodewell Products for the Treatment of Atopic Dermatitis

Detection of Aggressive Breast Tumors Using Tc-99m-NC100692

Text Messaging and Atopic Dermatitis

Phase 2b Study to Evaluate the Efficacy and Safety of ISB 830 in Adults With Moderate to Severe Atopic Dermatitis

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

An Ascending Multiple Dose Study of VTP-38543 in Adult Participants With Mild to Moderate Atopic Dermatitis

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

The Effect of Isosorbide Diesters Based Moisturizer on Skin Health

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement